Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Essex Bio-Technology ( (HK:1061) ) has provided an announcement.
Essex Bio-Technology has announced that its indirect subsidiary, Guangdong Hanfeng Baisheng Pharmaceutical Company Limited, has received approval from China’s National Medical Products Administration to register and commercialise its multi-dose Sodium Hyaluronate Eye Drops (0.3%) in mainland China. The product, formulated as 0.3% sodium hyaluronate in a 5ml:15mg dosage, is indicated for the treatment and symptomatic relief of a range of intrinsic ocular diseases, including Sjögren’s syndrome, Stevens-Johnson syndrome, dry eye syndrome, and for injuries arising from surgery, drugs, trauma, or contact lens use, potentially strengthening the company’s ophthalmic portfolio and market presence in the PRC.
The most recent analyst rating on (HK:1061) stock is a Hold with a HK$5.00 price target. To see the full list of analyst forecasts on Essex Bio-Technology stock, see the HK:1061 Stock Forecast page.
More about Essex Bio-Technology
Essex Bio-Technology Limited is a Hong Kong-listed pharmaceutical company focused on ophthalmic and other biopharmaceutical treatments, with operations in mainland China through subsidiaries such as Guangdong Hanfeng Baisheng Pharmaceutical Company Limited. The group develops and commercialises prescription therapies aimed at eye diseases and related conditions in the Chinese healthcare market.
Average Trading Volume: 688,380
Technical Sentiment Signal: Hold
Current Market Cap: HK$2.24B
See more data about 1061 stock on TipRanks’ Stock Analysis page.